NeuroSense Therapeutics Ltd. (NRSN) Income Statement
NRSN 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsNRSN revenue and net income
NRSN growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
NRSN quarterly EPS vs estimates
NeuroSense Therapeutics beat the analyst EPS estimate in 7 of the last 8 quarters.
NRSN income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | — | $22,000 | $97,000 | $89,000 | $3,000 | $3,000 | — |
| Gross profit | — | −$22,000 | −$97,000 | −$89,000 | −$3,000 | −$3,000 | — |
| Research & development | $6.2M | $5.7M | $7.3M | $6.4M | $3.1M | $2.5M | $898,000 |
| Sales, general & admin | $4.9M | $4.2M | $4.8M | $7.1M | $2.5M | $393,000 | $337,000 |
| Total operating expenses | $11.1M | $9.9M | $12.0M | $13.5M | $5.6M | $2.9M | $1.2M |
| Operating income | −$11.1M | −$9.9M | −$12.0M | −$13.6M | −$5.6M | −$2.9M | −$1.2M |
| Interest income | $13,000 | $2,000 | $178,000 | $91,000 | $0 | $61,000 | $18,000 |
| Interest expense | — | $311,000 | $550,000 | $15,000 | $1.2M | $1,000 | $5,000 |
| Income before taxes | −$11.1M | −$10.2M | −$10.1M | −$12.3M | −$4.0M | −$2.8M | −$1.2M |
| Income taxes | — | — | −$1 | −$1.1M | −$1.5M | $1,000 | $5,000 |
| Net income | −$11.1M | −$10.2M | −$10.1M | −$12.3M | −$4.0M | −$2.8M | −$1.2M |
| EBITDA | −$11.1M | −$9.9M | −$9.6M | −$12.2M | −$2.9M | −$2.8M | −$1.3M |
| EPS (diluted) | −$0.29 | −$0.54 | −$0.83 | −$1.07 | −$0.68 | −$0.72 | −$0.06 |
| Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | Jun '23 | Mar '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Research & development | $1.9M | $1.9M | $1.3M | $1.3M | $1.1M | $1.2M | $1.6M | $1.9M | $2.0M | $1.6M | $1.9M | $1.9M |
| Sales, general & admin | $1.3M | $1.3M | $1.1M | $1.1M | $685,000 | $946,000 | $1.5M | $1.1M | $1.3M | $1.3M | $1.6M | $1.1M |
| Total operating expenses | $3.2M | $3.2M | $2.3M | $2.3M | $1.8M | $2.1M | $3.0M | $3.0M | $3.3M | $2.9M | $3.5M | $3.0M |
| Operating income | −$3.2M | −$3.2M | −$2.3M | −$2.3M | −$1.8M | −$2.1M | −$3.0M | −$3.0M | −$3.3M | −$2.9M | −$3.5M | −$3.0M |
| Interest income | — | — | — | — | — | — | — | — | $3.7M | — | — | $62,000 |
| Interest expense | — | — | $8,500 | $8,500 | — | $41,000 | $2.2M | $2.4M | $2.2M | $12,000 | $276,000 | $310,000 |
| Income before taxes | −$3.2M | −$3.2M | −$2.4M | −$2.4M | −$1.8M | −$2.1M | −$857,000 | −$5.4M | −$3.0M | $784,000 | −$5.2M | −$2.9M |
| Income taxes | — | — | — | — | — | — | — | −$43,276 | — | $5.9M | −$2.2M | −$62,000 |
| Net income | −$3.2M | −$3.2M | −$2.4M | −$2.4M | −$1.8M | −$2.1M | −$857,000 | −$5.4M | −$3.0M | $784,000 | −$5.2M | −$2.9M |
| EBITDA | −$3.2M | −$3.2M | −$2.3M | −$2.3M | −$1.8M | −$2.1M | −$851,500 | −$3.0M | — | $3.0M | −$5.5M | −$2.6M |
| EPS (diluted) | $0.00 | −$0.04 | −$0.19 | −$0.06 | −$0.06 | −$0.11 | −$0.02 | −$0.35 | −$0.16 | $0.10 | −$0.44 | −$0.33 |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in NRSN's financial statements (latest annual report filed March 31, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
NRSN financial results
NeuroSense Therapeutics reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of $11.1 million. Diluted earnings per share came to −$0.29.
See the NRSN stock overview for the latest quote and news, or the NRSN chart for price history and technical indicators.
NRSN income statement FAQ
Does NeuroSense Therapeutics have revenue?
NeuroSense Therapeutics reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is NeuroSense Therapeutics profitable?
No. NeuroSense Therapeutics reported a net loss of $11.1 million in fiscal 2025.
How much does NeuroSense Therapeutics spend on research and development?
NeuroSense Therapeutics spent $6.2 million on research and development in fiscal 2025.
What are NeuroSense Therapeutics's earnings per share?
NeuroSense Therapeutics earned $-0.29 per diluted share in fiscal 2025, compared with $-0.54 a year earlier.
When does NeuroSense Therapeutics's fiscal year end?
NeuroSense Therapeutics's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 31, 2026.